COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH REAL-WORLD TREATMENT FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION IN CHINA

被引：0
|
作者：
Yang, L. [1 ]
Wu, J. [2 ]
机构：
[1] Peking Univ, Beijing, Peoples R China
[2] Bayer Healthcare Co Ltd, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.381
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV60
引用
收藏
页码：S63 / S63
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF RIVAROXABAN IN THE PREVENTION OF STROKE IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS IN ITALY
    Capri, S.
    Veneziano, M.
    Ricciardi, W. G.
    D'Ausilio, A.
    Pedone, M. P.
    Bianchi, C.
    VALUE IN HEALTH, 2013, 16 (07) : A525 - A526
  • [2] Cost-effectiveness of apixaban compared to edoxaban for stroke prevention in non-valvular atrial fibrillation
    Lip, G. Y. H.
    Kongnakorn, T.
    Lanitis, T.
    Phatak, H.
    Liu, J. X. C.
    Kuznik, A.
    Lawrence, J.
    Dorian, P.
    EUROPEAN HEART JOURNAL, 2014, 35 : 1108 - 1109
  • [3] Cost-effectiveness of Apixaban Against Dabigatran and Rivaroxaban for Stroke Prevention in Non-valvular Atrial Fibrillation Patients
    Lip, Gregory Y.
    Lanitis, Tereza
    Kongnakorn, Thitima
    Phatak, Hemant
    Liu, Larry Z.
    Lawrence, John
    Dorian, Paul
    CIRCULATION, 2014, 130
  • [4] Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis
    de Jong, Lisa Aniek
    Gout-Zwart, Judith J.
    van den Bosch, Marina
    Koops, Mike
    Postma, Maarten J.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 306 - 318
  • [5] Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain
    Gonzalez-Juanatey, Jose R.
    Alvarez-Sabin, Jose
    Lobos, Jose M.
    Martinez-Rubio, Antoni
    Reverter, Joan C.
    Oyagueez, Itziar
    Gonzalez-Rojas, Nuria
    Becerra, Virginia
    REVISTA ESPANOLA DE CARDIOLOGIA, 2012, 65 (10): : 901 - 910
  • [6] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS RIVAROXABAN FOR PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN SPAIN
    Canal Fontcuberta, G.
    Escolar Albaladejo, G.
    Betegon Nicolas, L.
    de Salas-Cansado, M.
    Rubio-Rodriguez, D.
    Rubio-Terres, G.
    VALUE IN HEALTH, 2013, 16 (07) : A523 - A523
  • [7] Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting
    Hori, Masatsugu
    Tanahashi, Norio
    Akiyama, Sayako
    Kiyabu, Grace
    Dorey, Julie
    Goto, Rei
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (03) : 252 - 261
  • [8] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS WARFARIN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION IN THE JAPANESE HEALTHCARE SETTING
    Hori, M.
    Tanahashi, N.
    Akiyama, S.
    Kiyabu, G.
    Dorey, J.
    Goto, R.
    VALUE IN HEALTH, 2019, 22 : S554 - S555
  • [9] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    Clinical Drug Investigation, 2014, 34 : 9 - 17
  • [10] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    CLINICAL DRUG INVESTIGATION, 2014, 34 (01) : 9 - 17
12345